Introduction
============

*Mycobacterium tuberculosis*, the causative agent of Tuberculosis (TB), remains the biggest bacterial killer with 1.3 million deaths per year ([@B36]). Emergence of genetic drug resistance and persistence of infection despite extensive chemotherapy represent two major issues in current TB treatment regimens ([@B5]; [@B13]). TB drugs, like most antibiotics, target specific macromolecules. Antibiotic resistance arises mainly from mutations in target genes ([@B6]). Genetic resistance occurs readily in patients due to non-compliance to lengthy (6--24 months) multi-drug regimens and spatio-temporal pockets of monotherapy ([@B29]). Persistence of infection is thought to be due to various types of metabolically quiescent non-growing drug tolerant bacteria. Several culture models have been developed to study persister bacilli *in vitro*. A first type of mycobacterial persister may pre-exist in growing cultures or is induced upon treatment of growing cultures with drugs. Isoniazid for instance shows a bi-phasic kill pattern ([@B1]; [@B10]). An initial rapid kill is followed by a phase of reduced killing leaving intact a small subpopulation of drug tolerant persisters ([@B20]). A second type of persisters can be grown *in vitro* by exposing a replicating culture to adverse culture conditions. Growth is terminated and the non-replicating organisms display drug tolerance ([@B8]; [@B32]). The Wayne model of persistence ([@B34]) for instance exposes the obligate aerobe to hypoxia, a micro-environmental condition demonstrated for TB lesions *in vivo* ([@B24]). Upon oxygen depletion the whole growing culture shifts down to a state of non-replicating persistence. A current working model suggests that killing both persister types may be required to achieve treatment shortening ([@B11]; [@B5]). Ideally new TB drugs should kill persister bacilli and show a low propensity for the development of genetic drug resistance.

Bacterial membrane integrity and its associated homeostatic functions, such as maintenance of ion gradients, is essential regardless of the metabolic status of the cell ([@B18]). The large number of antimicrobial peptides made by the host validates the membrane as an antibacterial target site and successful clinical use of a few membrane-targeting antibiotics, supports this notion ([@B18]). Furthermore, resistance development to membrane-targeting antibiotics is expected to be slow as the target is the product of complex biosynthetic pathways, as opposed to a single macromolecule. This notion is supported by the slow emergence of resistance against membrane targeting antibiotics used in the clinic ([@B18]). Current TB drugs do not target the membrane. Here, we used boromycin, an old polyether macrolide antibiotic isolated from *Streptomyces antibioticus* to ask whether targeting the mycobacterial membrane may be a chemotherapeutic intervention level that would achieve both killing of non-growing persister bacilli and slowing down the development of genetic drug resistance. Boromycin was the first natural product and the first antibiotic found to contain the trace element boron ([@B19]). Its structure was elucidated by degradation studies and X-ray analysis ([@B12]) and is shown in **Figure [1](#F1){ref-type="fig"}**. Boromycin's *in vitro* bactericidal activity was first reported in 1967 against Gram positive bacteria. The antibiotic was shown to act as ionophore causing cellular potassium ion loss leading to growth arrest and cell death. The compound is ineffective against Gram negative bacteria where the outer membrane appears to block access of the compound to the cytoplasmic membrane ([@B19]; [@B28]).

![**Structure of boromycin ([@B19])**.](fmicb-07-00199-g001){#F1}

Materials and Methods {#s1}
=====================

Strains, Culture Conditions, and Chemicals
------------------------------------------

*Mycobacterium tuberculosis* H37Rv (ATCC 27294) and *M. bovis* BCG (ATCC 35734) liquid cultures were grown in Middlebrook 7H9 broth (BD Difco) supplemented with 0.5% albumin, 0.2% glucose, 0.085% sodium chloride, 0.5% glycerol, 0.05% Tween 80. Solid medium cultures were grown on Middlebrook 7H10 agar (BD Difco) supplemented with 0.5% albumin, 0.2% glucose, 0.085% sodium chloride, 0.5% glycerol, 0.0003% catalase, and 0.006% oleic acid as described previously ([@B23]). *Staphylococcus aureus* (ATCC 29213), *S. epidermidis* (ATCC 14990), *Enterococcus faecalis* (ATCC 29212), *Escherichia coli* (ATCC 25922), *Acinetobacter baumannii* (ATCC19606), and *Klebsiella pneumonia (*ATCC BAA-1705) liquid cultures were grown in LB media (BD Difco). To generate hypoxic non-growing mycobacterial cultures, bacteria were grown in sealed glass tubes with stirring as described previously ([@B25]). HepG2 (ATCC HB.8065) and Vero (ATCC CCL-81) cells were cultured at 37°C with 5% CO~2~ atmosphere in DMEM media (Gibco) complemented with 10% FBS heat-inactivated (Gibco), penicillin (100 U/mL, Gibco) and streptomycin (100 μg/mL, Gibco). Red blood cells were obtained from Interstate Blood Bank, Inc. Laboratory, USA. Boromycin was purchased from AdipoGen. Carbonyl cyanide m-chlorophenyl hydrazone (CCCP), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Triton X-100, and isoniazid were purchased from Sigma--Aldrich.

Growth Inhibition and Bactericidal Assays
-----------------------------------------

Mininum Inhibitory Concentrations (MICs) were determined in broth as described previously by the broth dilution method ([@B26]; [@B14]; [@B23]) using turbidity (optical density) as a proxy for growth ([@B26]). We report MIC~50~ and MIC~90~, the concentrations that inhibit 50 and 90% of growth, respectively, as compared to the untreated control. Bactericidal activities, i.e., 'Minimal bactericidal concentration' (MBC~99~) for growing bacteria, and 'Wayne cidal concentration' (WCC~99~) for hypoxic non-growing bacilli were determined as described previously ([@B26]; [@B23]). Controls of Wayne's model of hypoxia included treatment with 5 μM of isoniazid or moxifloxacin resulting in no any bactericidal activity and 10 fold killing, respectively. Exponentially growing cultures or hypoxic non-growing cultures were exposed to various drug concentrations for 5 days and then plated for CFU (colony forming unit) determination.

Spontaneous Resistant Mutant Selection
--------------------------------------

*Mycobacterium bovis* BCG was grown to mid log phase (O.D. 600 = 0.4--0.6) and10^8^ CFU were plated per 7H10 standard agar plate containing one, two or four times the MIC~90~ concentration of boromycin. In order to reach 10^9^ CFU and not overload the plates, we plated 10 times 10^8^ CFU on 10 different plates. The plates were incubated for a total of 8 weeks ([@B14]).

Time-Kill, Cell-Content Release, Membrane Potential, and ATP Level Determinations
---------------------------------------------------------------------------------

Time-kill curves were determined as follows: 10^7^ CFU inoculum of *M. bovis* BCG were treated with MIC~90~ of boromycin or Isoniazid and samples were taken at various time points for CFU determination on agar plates. To assess the effect of boromycin on the release of cell content, we transformed *M. bovis* BCG with plasmid pGMEH-P38-mRFP ([@B21]) (pGMEH-P38-mRFP was a gift from Dirk Schnappinger, Addgene plasmid \# 27058) encoding mCherry Red Fluorescent Protein (mRFP) under the control of a strong promoter. We subjected this strain for 2 days to MIC~90~ of INH, boromycin or left it untreated. Supernatant was collected by two serial centrifugations. Fluorescence was measured using Tecan Infinite M200Pro plate reader (λ587/630 nm). Similarly, the effect of boromycin on the membrane potential was measured using the Baclight Bacterial Membrane Potential Kit (Life Technologies) according to the supplier's recommendations. ATP level was determined using the BactiterGlo kit (Promega) according to manufacturer's recommendations.

Cytotoxicity Assays
-------------------

The MTS (Promega) reduction assay was used to assess HepG2 (ATCC HB-8065) or Vero (ATCC CCL-8) cell viability after exposure to boromycin according to manufacturer's guidelines. Absorbance was read with a Tecan M200Pro plate reader at 570 nm. Optical density (O.D.) was plotted as a function of drug concentration and cytocidal concentrations were determined. CCCP was used as a cytotoxic positive control. Hemolytic activity of boromycin was evaluated by exposing 10^6^ red blood cells to two fold serial dilutions of compounds in phosphate-buffered saline for 24 h. Red blood cells were subsequently centrifuged at 1000 g for 10 min and the supernatant was collected and homogenized by vortexing. Absorbance was read at 540 nm. Triton X-100 treated control was used to define 100% of hemoglobin release.

Results
=======

Boromycin Kills Growing and Non-growing Persister Mycobacteria, Shows a High Selectivity Index, and No Detectable Resistance
----------------------------------------------------------------------------------------------------------------------------

We first determined whether boromycin shows anti-mycobacterial activity or whether the outer membrane of mycobacteria would, similar to the outer membrane in Gram negative bacteria, cause intrinsic resistance to the antibiotic. Virulent *M. tuberculosis* H37Rv and its closely related, BSL2 compatible, cousin *M. bovis* BCG were used as testing strains. The broth dilution method was employed to determine MIC~50~ and MIC~90~ (minimum inhibitory concentrations that inhibit 50 and 90% of growth) by turbidity measurements and MBC~99~ (minimum bactericidal concentration that causes a 100 fold kill) was obtained by recovering CFU on agar ([@B26]). We also determined WCC~99~ (minimum bactericidal concentration that causes a 100-fold kill in the Wayne model), i.e., the concentration that kills hypoxic non-replicating persister bacilli ([@B23]). **Table [1](#T1){ref-type="table"}** shows that boromycin displayed an attractive growth inhibition potency with MIC~50~ values of around 80 nM and bactericidal activity against both replicating and non-replicating tubercle bacilli with identical MIC~90~, MBC~99~, and WCC~99~ values of 200 nM. These results show that boromycin possesses very potent anti-mycobacterial activity despite the presence of an outer membrane in this group of bacteria and that its cidal activity is independent of the replication status of the bacilli, which means that the antibiotic kills not only aerated growing cultures but also hypoxic non-growing cultures (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). **Table [1](#T1){ref-type="table"}** also shows that boromycin displayed potent growth inhibition and bactericidal activity against Gram positive pathogens including *S. aureus, S. epidermidis*, and *E. faecalis* but was inactive against Gram negative bacteria including *E. coli, A. baumannii*, and *K. pneumoniae* confirming previous reports ([@B19]).

###### 

Antibacterial and cytotoxic activities of Boromycin.

                            Antibacterial activity (μM)                       
  ------------------------- ------------------------------ ------------ ----- -----
  *M. tuberculosis* H37Rv   0.08                           0.2          0.2   nd
  *M. bovis* BCG            0.05                           0.2          0.2   0.2
  *S. aureus*               0.1                            0.3          0.6   na
  *S. epidermidis*          0.1                            0.3          0.3   na
  *E. faecalis*             0.15                           0.2          0.4   na
  *E. coli*                 \>100                          \>100        na    na
  *A. baumannii*            \>100                          \>100        na    na
  *K. pneumoniae*           \>100                          \>100        na    na
                                                                              
                            **Cytotoxicity (μM)**                             
                            **CC~50~**                     **CC~90~**         
                                                                              
  HepG2                     35                             \>50               
  Vero                      25                             \>50               
                                                                              
                            **Haemolytic activity (μM)**                      
                            **HC~50~**                     **HC~90~**         
                                                                              
  Human red blood cells     40                             \>50               
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, haemolytic concentration that induces lysis of 50 and 90% of red blood cells, respectively. n.d., not determined; n.a., not applicable.

To determine boromycin's selectivity index, we measured cytotoxicity against mammalian HepG2 and Vero cells using a tetrazolium reduction viability assay ([@B30]), and its haemolytic activity against human red blood cells using an hemoglobin-release assay ([@B9]). Boromycin's cytocidal (CC~50~) and haemolytic (HC~50~) concentrations (concentrations that kills 50% of HepG2 or Vero cells and induces the lysis of 50% of red blood cells), were shown to be 35, 25, and 40 μM, respectively, (**Table [1](#T1){ref-type="table"}**). These results suggest that boromycin has a high selectivity for the mycobacterial membrane with a selectivity index (CC~50~/MIC~50~) of more than 300.

To determine whether boromycin kills growing cultures completely or whether the antibiotic shows a -- for many TB drugs typical -- biphasic kill curve, time-kill experiments were conducted in which we quantified the reduction of CFU as a function of exposure time. **Figure [2](#F2){ref-type="fig"}** shows the typical biphasic kill curve of isoniazid. After an initial reduction of CFU the curve levels off and leaves intact a population of viable non-growing persister bacteria. In contrast boromycin showed a monophasic kill curve resulting in an apparent sterilization of the culture.

![**Time-kill curve of boromycin compared to Isoniazid.** Exponentially growing cultures of *Mycobacterium bovis* BCG were treated with boromycin (BORO, 0.2 μM = 1x MIC~90~) or Isoniazid (INH, 0.5 μM = 1x MIC~90~) and CFU were enumerated at the time points indicated. Experiments were conducted three times. Shown are the averages with standard deviations. LOD, limit of detection (30 CFU/ml).](fmicb-07-00199-g002){#F2}

To determine spontaneous resistance mutation frequencies for boromycin we plated twice 10^9^ CFU logarithmic phase *M. bovis* BCG cultures on agar plates containing one, two or four times the MIC~90~ of the antibiotic. No boromycin resistant colonies could be identified even after extended incubation of the selection plates for 8 weeks. This result shows that the spontaneous resistance mutation frequency of the tubercle bacillus against boromycin is smaller than 10^-9^/CFU. In contrast Isoniazid selection delivered resistant strains at a frequency of 10^-6^/CFU.

Boromycin Acts as Potassium Ionophore and Causes Collapse of the Membrane Potential
-----------------------------------------------------------------------------------

Boromycin was previously shown in *B. subtilis* to act as a potassium ionophore and to cause loss of the bacterium's potassium ion gradient. Addition of potassium salt to the medium -- but not addition of (divalent) magnesium salt blocked the growth inhibitor activity of the drug ([@B28]). We tested the protective effect of high concentrations of potassium (20 mg/mL) or magnesium (10 mg/mL) cations in the culture media while subjecting *M. bovis* BCG to boromycin treatment at MIC~50~. In standard broth, we observed the expected 50% growth inhibition effect (**Figure [3A](#F3){ref-type="fig"}**). This growth inhibition was reduced to 10% in presence of KCl whereas it was unaffected by the addition of MgCl~2~ (**Figure [3A](#F3){ref-type="fig"}**). In contrast, addition of KCl did not affect growth inhibition by isoniazid (Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}). These results suggest that boromycin's mechanism of action against mycobacteria is similar to its actions against Gram positive bacteria, which is to say that the polyether macrolide appears to act as a potassium ionophore. We also tested whether the medium pH influenced the growth inhibitory activity of the antibiotic (pH 5.5, 6.4, and 9), which was not the case (Supplementary Figure [S3](#SM1){ref-type="supplementary-material"}), consistent with boromycin's neutral (i.e., not involving protons) carrier property ([@B19]).

![**Mechanism of action of boromycin. (A)** Effect of cations added to the medium on growth inhibition by boromycin. Exponentially growing *M. bovis* BCG culture was exposed to MIC~50~ (0.05 μM) boromycin either in standard medium (Mock) or to medium with added potassium chloride (+KCl, 20 mg/ml) or magnesium chloride (+MgCl~2~, 10 mg/ml). The effect on growth was determined by turbidity measurement after 5 days. Percent inhibition compared to boromycin-free control cultures grown in standard medium is shown. **(B)** Effect of boromycin on the membrane potential. Exponentially growing *M. bovis* BCG culture was exposed to MIC~90~ (0.2 μM) boromycin for 2 days after which the membrane potential was measured by the DiOC2, (3,3′-Diethyloxacarbocyanine Iodide) fluorescence assay (see Materials and Methods). Carbonyl cyanide m-chlorophenyl hydrazone (CCCP, 50 μM), positive control. INH, Isoniazid MIC~90~ (0.5 μM). **(C)** Effect of boromycin on the intracellular ATP level. Exponentially growing *M. bovis* BCG culture was exposed to MIC~90~ (0.2 μM) boromycin for 2 days after which the ATP content was measured was measured by ATP-dependent luciferin/luciferase assay (see Materials and Methods). INH, Isoniazid MIC~90~ (0.5 μM). RLU, relative luminescence unit. **(D)** Effect of boromycin on cytoplasmic protein leakage. Exponentially growing *M. bovis* BCG culture was exposed to MIC~90~ (0.2 μM) boromycin for 2 days after which release of Red fluorescence protein (RFP) was measured in the supernatant. INH, Isoniazid, MIC~90~ (0.5 μM). RFU, relative fluorescence unit. B.B: positive control, culture disrupted by bead beating. **(A--D)**: Shown are the averages of three independent experiments with standard deviations and Student *T*-test statistical significances given by a two-tailed P values with ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01.](fmicb-07-00199-g003){#F3}

If boromycin indeed acts as an ionophore and causes the collapse of the potassium gradient across the bacillus' membrane we expect to see an effect of the compound on the membrane potential. To determine whether this is the case, we measured the effect of the antibiotic on the membrane potential employing the 3,3-Diethyloxacarbocyanine iodide (DiOC2) probe which accumulates in cells in a membrane potential-dependent manner ([@B27]). Upon accumulation, the dye forms aggregates that emit a red fluorescence signal (λ488/630 nm) whereas a reduced membrane potential prevents accumulation and results in green fluorescence emission (λ488/520 nm), that is the red/green ratio reflects the membrane potential status. **Figure [3B](#F3){ref-type="fig"}** shows that as expected, boromycin treatment caused a marked depolarization of the membrane as illustrated by the drop in the red/green ratio, similar to the effect of the uncoupler carbonyl cyanide m-chloro phenyl hydrazone (CCCP). In comparison, isoniazid treatment affected the membrane potential only moderately. To characterize the cellular consequences of boromycin exposure and collapse of the membrane potential further, we measured the impact of the ionophore on the cellular ATP level. ATP synthesis requires membrane polarization and we predicted that boromycin treatment would results in a marked reduction in ATP level. We used the BactiterGlo kit which makes use of the ATP-dependent luciferin/luciferase reaction to measure ATP. **Figure [3C](#F3){ref-type="fig"}** shows a drastic reduction of the ATP level upon boromycin exposure, which was not observed upon Isoniazid treatment as reported by others ([@B22]). Finally, we show in **Figure [3D](#F3){ref-type="fig"}** that boromycin treatment results in leakage of cytoplasmic protein. We employed a strain expressing a plasmid-encoded red fluorescent protein (λ587/630 nm) and subjected cultures to MIC~90~ of boromycin. We used centrifugation to pellet the treated cultures and measured the cell-content release, reflected by the red fluorescence signal measured in the supernatant. Cultures disrupted by bead beating were used as a positive control. Boromycin treatment correlated with a marked cell-content release as reflected by the increase in red fluorescence. Treatment with Isoniazid was associated with a moderate increase in the fluorescence signal. It has previously been suggested that isoniazid treatment leads to moderate cell lysis ([@B33]).

Discussion
==========

Boromycin is a polyether macrolide antibiotic with selective activity against Gram positive bacteria where it acts as ionophore for potassium ions. The antibiotic is ineffective against Gram negative bacteria where the outer membrane appears to block access of the compound to the cytoplasmic membrane. Here we show boromycin is active against *Mycobacterium tuberculosis* which, similar to Gram negative bacteria, possesses an outer membrane. Boromycin is a potent, submicromolar inhibitor of mycobacterial growth with submicromolar bactericidal activity against growing and non-growing drug tolerant persister bacilli. Exposure to boromycin resulted in a loss of membrane potential, reduction of the intracellular ATP level and leakage of cytoplasmic protein. Consistent with boromycin acting as a potassium ionophore addition of KCl to the medium blocked its antimycobacterial activity. In contrast to the potent antimycobacterial activities cytotoxicity and haemolytic activity were low with a selectivity index of more than 300. Spontaneous resistant mutants could not be isolated indicating a very low spontaneous resistance mutation frequency of less than 10^-9^/CFU.

Ionophores are currently not being used in medicine mainly because of their generally poor selectivity. However, these antibiotics are widely in use in livestock veterinarian medicine ([@B31]). It is interesting to note that this class of molecules recently gained attention as potential anti-cancer agents. Salinomycin, another polyether monovalent cation ionophore, has been shown to possess high specificity against cancer stem cells ([@B15]) and has now entered clinical trial studies ([@B35]). Similar compounds are actively considered for their antibacterial and anti-parasitic properties ([@B16]; [@B17]; [@B2],[@B3],[@B4]; [@B7]). Here we add to the growing list of potentially therapeutically interesting ionophores: we identified boromycin as a potent and selective antimycobacterial compound. Further studies will determine the efficacy of this new antimycobacterial in TB mouse models. Our findings also suggest that it may be worthwhile to consider a so far underexplored approach in TB drug discovery: targeting the mycobacterial cell membrane as opposed to specific macromolecules may represent an attractive strategy to slow down genetic resistance development. Importantly, this chemotherapeutic intervention level appears to be an effective way to kill drug tolerant persister bacilli. Therefore, membrane function targeting agents could contribute to the development of novel treatment shortening anti-TB combination regimens.
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